ArticleJournal of translational medicine2025

Analysis of the efficacy and influencing factors of double-dose furmonertinib for advanced EGFR ex20ins non-small cell lung cancer.

Kexin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.